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Summary
Immunodeficiency in association with centromere insta-
bility of chromosomes 1, 9, and 16 and facial anomalies
(ICF syndrome) is a rare autosomal recessive disorder.
ICF patients show marked hypomethylation of their
DNA; undermethylation of classical satellites II and III
is thought to be associated with the centromere insta-
bility. We used DNA from three consanguineous families
with a total of four ICF patients and performed a total
genome screen, to localize the ICF syndrome gene by
homozygosity mapping. One chromosomal region
(20q11-q13) was consistently found to be homozygous
in ICF patients, whereas all healthy sibs showed a het-
erozygous pattern. Comparison of the regions of ho-
mozygosity in the four ICF patients localized the ICF
locus to a 9-cM region between the markers D20S477
and D20S850. Analysis of more families will be required,
to refine the map location further. Isolation of the gene
associated with the ICF syndrome not only will give
insight into the etiology of the ICF syndrome but will
also broaden our understanding of DNA methylation
processes.
Introduction
Immunodeficiency in association with centromere insta-
bility of chromosomes 1, 9, and 16 and facial anomalies
(ICF syndrome [MIM 242860]) is an extremely rare con-
dition first described nearly 20 years ago (Hulte´n 1978;
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Tiepolo et al. 1979); only 20 patients have been reported
in the literature (Smeets et al. 1994; Brown et al. 1995;
Franceschini et al. 1995). ICF syndrome is characterized
by the presence of an immunodeficiency—either a com-
bined immunodeficiency or a deficiency of a single im-
munoglobulin—in combination with facial dysmorph-
isms, including epicanthic folds, telecanthus, a flat nasal
bridge, macroglossia with a protruding tongue, andmild
micrognathia. ICF patients generally suffer from recur-
rent and prolonged respiratory infections that are due
to their immunodeficiency. All ICF patients have insta-
bility of pericentric heterochromatin of chromosomes 1,
9, and/or 16. DNA methylation studies in ICF patients
showed hypomethylation of classical satellites II and III,
which are major components of constitutive hetero-
chromatin (Jeanpierre et al. 1993; Schuffenhauer et al.
1995; Miniou et al. 1997).
The existence of several families with several affected
sibs suggests a genetic predisposition to ICF (Valkova et
al. 1987). In addition, the majority of ICF patients have
been born from consanguineous marriages, suggesting
that ICF is transmitted as an autosomal recessive trait
(Valkova et al. 1987). The extremely rare occurrence of
the ICF syndrome and the existence of affected, inbred
individuals make the localization of the gene underlying
this disorder a suitable target for homozygosity map-
ping. This mapping approach is based on the inheri-
tance, from a common ancestor, of two identical copies
of the disease locus, by the affected inbred child—that
is, homozygosity by descent (HBD) (Lander and Botstein
1987). Homozygosity mapping has been used to localize
several recessive disease genes, including Rogers syn-
drome (Neufeld et al. 1997), Hallervorder-Spatz syn-
drome (Taylor et al. 1996), and urofacial (Ochoa) syn-
drome (Wang et al. 1997).
The size of the region around a disease locus that
shows HBD in an affected inbred individual is deter-
mined by the number of meiotic steps that separate the
affected individual from the common ancestor who car-
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Figure 1 Pedigree ICF family 1. The parents go back to a com-
mon ancestor 5 generations ago.
ried a single copy of the disease chromosome. A rela-
tively large region of ∼30 cM around the disease locus
can be expected to show HBD when the patient is the
product of a first-cousin marriage (Terwilliger et al.
1997). In contrast, a separation by 12 meiotic steps
yields, on average, a region of HBD of only 16 cM
around a disease locus. Consequently, as the number of
meiotic steps increases, the length of the conserved an-
cestral segment that will be homozygous by descent be-
comes smaller. When the conserved fragments become
too small, they may be easily missed if markers with an
average spacing of 10 cM are used, and a higher density
of markers will be needed.
We used homozygosity mapping in three consanguin-
eous ICF families. One ICF family with two affected
brothers and common ancestors six generations ago (fig-
ure 1) was initially used to perform a genomewide scan
to find regions that were homozygous and shared be-
tween the two affected sibs. Six different chromosomal
regions were identified, and the remaining two consan-
guineous families were used to confirm and delimit a
region on chromosome 20 that was homozygous in all
four affected inbred individuals. Comparing the regions
of homozygosity in the four ICF patients maps the locus
responsible for ICF syndrome (ICF) to a 9-cM interval
on 20q11-q13.
Subjects and Methods
Subjects
We investigated three families containing four ICF pa-
tients and seven unaffected family members. All four
patients are the offspring of consanguineous unions. The
Dutch family 1 was previously reported as an apparently
nonconsanguineous family (Smeets et al. 1994). Exten-
sive genealogical studies identified, for the parents, a
common ancestor five generations ago (figure 1). The
clinical and laboratory data for patient P1 were de-
scribed by Smeets et al. (1994). The diagnosis of ICF in
his brother, P2, born in 1994, was made soon after birth,
by means of cytogenetic studies. Treatment for agam-
maglobulinemia was started at 6 weeks of age. Patient
P2 is doing well and has never had serious infections.
In the two Turkish families 2 and 3, there had been
first-cousin marriages. Patient P3 of family 2, born in
1996, was admitted to hospital for respiratory infections
and diarrhea. Cytogenetic studies showed the typical ICF
abnormalities. She displayed minor facial abnormalities.
Immunological studies showed agammaglobulinemia,
for which she received immunoglobulin substitution. Pa-
tient P4 of family 3, born in 1983, was diagnosed as
having ICF syndrome, by means of cytogenetic studies.
Despite treatment for agammaglobulinemia, she suffered
from recurrent respiratory infections. At the age of 11
years, she died from sepsis after surgery for gastroeo-
sophageal reflux.
Marker Analysis
DNA was extracted from 20 ml blood by means of
standard procedures (Miller et al. 1988). The genome
screen was performed with markers from theMarshfield
screening set, v6 (Center for Medical Genetics). These
markers have an average spacing of 10 cM and an av-
erage heterozygosity of ∼0.75. Reverse primers were la-
beled with either 6-FAM, HEX, or TET fluorescent dyes
(Isogen Biosciences), which allowed analysis of a high
density of markers on an automated ABI377 DNA se-
quencer. PCR reactions were performed in an ABI877
in a 10-ml volume containing 30 ng template DNA, 25
ng each oligonucleotide primer, 200 mM each dNTP,
and 0.4 units Amplitaq Gold (Perkin Elmer), in 1 #
PCR buffer II with 2.5 mMMgCl2 (Perkin Elmer). DNA
was initially denatured at 94C for 10 min and was then
subjected to 32 cycles of 94C for 30 s, 55C for 30 s,
and 72C for 30 s, followed by a final extension step of
10 min at 72C. One microliter of the PCR reaction was
mixed with 1 ml formamide, 0.25 ml GS-500 size stan-
dard (Perkin Elmer), and 0.25 ml Blue Dextran (Perkin
Elmer) and separated on nondenaturing 5% polyacryl-
amide gels on an ABI377. Gel images were analyzed by
use of GeneScan 2.1 (Perkin Elmer). Allele sizes of the
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Figure 2 Genetic map and distances of the chromosome 20
markers. The location of the ICF gene is based on the region of ho-
mozygosity in all four patients. The distances between the markers
are in centimorgans and are based on previously published data (Co-
operative Human Linkage Center map: Buetow et al. 1994; Ge´ne´thon
map: Dib et al. 1996) or were extracted from the CEPH database.
individual markers were determined by use of Geno-
Typer 2.0 (Perkin Elmer).
CEPH reference samples (1331-02 and 1347-02) were
included, to determine the appropriate size of the alleles.
Allele frequencies for the Dutch population in this and
other studies in our laboratory are generally in good
agreement with published allele frequencies. For the
Turkish population and, in particular, for isolated com-
munities in Turkey, accurate allele frequencies are
unavailable.
Homozygosity Mapping
A total genome screen using 338 markers was per-
formed on DNA from four members of family 1 (M1,
F1, P1, and P2). For each marker, we determined
whether the two affected sibs (P1 and P2) were heter-
ozygous or homozygous for the same marker alleles. All
genomic regions in which two or more consecutive
markers showed homozygosity by state were studied fur-
ther by screening an additional ICF family (family 2)
and an isolated patient (family 3) with the samemarkers.
Localization of the ICF Locus to 20q11-q13
To determine the region of homozygosity on chro-
mosome 20 more precisely, we used additional markers:
D20S111, D20S200, D20S850, D20S108, D20S119,
D20S888, and D20S887. The map positions of these
markers with respect to the chromosome 20 markers
already analyzed during the genome screen are depicted
in figure 2. Multipoint LOD scores were calculated by
use of the computer program MAPMAKER/HOMOZ
(Kruglyak et al. 1995), with allele frequencies as pub-
lished for Caucasians. In addition, for the Turkish fam-
ilies 2 and 3, multipoint LOD scores were also calculated
with a lower threshold of 0.25 for all allele frequencies.
This threshold corresponds to the weighted average of
allele frequencies for markers with heterozygosity equal
to 0.75.
Results
Genome Screen
Initially, DNA from two affected ICF sibs from family
1 was analyzed with 338 markers (covering ∼90% of
the genome), yielding 45 markers (13%) that showed
homozygosity by state in both affected sibs. The ho-
mozygous markers were scattered throughout the ge-
nome. However, clusters of two or three adjacent ho-
mozygous markers were identified on 2p, 6q, 8q, 10p,
14q, and 20q. These six regions were considered to be
putative ICF candidate regions needing further investi-
gation. Three different approaches were followed to con-
firm or exclude the presence of the ICF locus for each
of these six loci: (i) typing two additional families (fam-
ilies 2 and 3), (ii) haplotype analysis to determine
whether the regions were also identical by descent, and
(iii) typing the healthy sib from family 1.
Further Examination of ICF Candidate Regions and
Mapping the ICF Locus to 20q
Family 2 was typed for markers from the six homo-
zygous regions observed in family 1 together with two
flanking markers for each region (25 markers total). Of
these, 11 markers, including 4 consecutive markers from
14q (D14S53, D14S606, D14S610, and D14S617) and
806 Am. J. Hum. Genet. 63:803–809, 1998
Table 1
Multipoint LOD Scores between ICF Syndrome and
Chromosome 20 Markers
Markera
Multipoint LOD Score
Family 1 Family 2 Family 3 Total
D20S194*  1.57 1.878 
D20S604*  1.60 .13 
D20S470* 2.81 1.34 1.92 2.23
D20S477* 3.21 1.45 1.97 2.68
D20S111 3.20 1.45 .86 5.50
D20S200 3.17 1.45 1.10 5.72
D20S478* 3.00 1.45 1.17 5.62
D20S850 .43 1.45 1.19 3.07
D20S108 .43 1.45 1.19 3.07
D20S119 1.30 1.45 1.19 3.94
D20S481* .43 1.45 1.19 3.07
D20S888 .43 2.80 1.19 1.17
D20S887 .43 2.49 1.18 .88
D20S109* .43 99 1.18 97.39
D20S1085* .37 .17 1.11 1.34
a The markers originally analyzed in the total genome
screen are marked with an asterisk.
Figure 3 Simplified pedigrees and genotypes in the region of homozygosity. Families 2 and 3 are first-cousin marriages. Dashes (–) indicate
genotypes that were not determined. The regions of homozygosity in the affected children are boxed.
4 consecutive markers from 20q (D20S470, D20S477,
D20S478, and D20S481), showed homozygosity by
state in patient P3. However, haplotype analysis ex-
cluded 14q as a likely location for the ICF locus. Al-
though the two affected sibs from family 1 (P1 and P2)
showed homozygosity by state for marker alleles at
D14S606 and D14S610, their mother was homozygous
for these markers. For informative markers flanking this
interval, the two affected sibs did not share their ma-
ternal allele (data not shown).
For family 3, only DNA from the proband was avail-
able. Analysis of chromosome 20 markers showed ho-
mozygosity for four successive markers from 20q
(D20S478, D20S481, D20S109, and D20S1085). None
of the three healthy sibs (families 1 and 2) that were
included showed homozygosity for this 20q region.
Interval Mapping
Further investigation with seven additional polymor-
phic markers and a comparison of the regions of ho-
mozygosity observed in the four ICF patients placed the
ICF locus, in individual P4, telomeric to D20S477 and,
in individuals P1 and P2, centromeric to D20S850.
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Figure 4 Results of linkage analysis between the ICF locus and 16 markers on chromosome 20q11-q13. The positions of the markers
are indicated by triangles.
Therefore, the interval between D20S477 and D20S850
delimits the ICF locus to a region of X9 cM (figure 3).
This chromosomal location by haplotype analysis was
in agreement with the results of the multipoint LOD
score analysis (see table 1 and figure 4). The peak mul-
tipoint LOD scores ( ) were obtained at D20S111Z 1 5
( ), D20S200 ( ), and D20S478 (Z  5.50 Z  5.72 Z 
). The peak multipoint LOD scores were derived5.62
mainly from the Dutch family 1 ( , 3.17, andZ  3.20
3.00, respectively). The multipoint LOD score results
were not sensitive to the specified allele frequencies
(maximum reduction in multipoint LOD score 0.07;
data not shown).
Two possible candidate genes from the 20q region
were investigated further: adenosine deaminase (ADA)
and S-adenosylhomocysteine hydrolase (ACHY or
SAHH). Deficiency of ADA or SAHH can lead to DNA
hypomethylation, a phenomenon that has been dem-
onstrated in ICF patients (Schuffenhauer et al. 1995;
Miniou et al. 1997). The enzyme activities of ADA and
SAHH were measured in lymphocytes of three ICF pa-
tients (P1, P2, and P3) but appeared to be normal (data
not shown). Therefore, ICF is not caused by deficiency
of ADA or SAHH.
Discussion
The locus for the ICF syndrome was localized by ho-
mozygosity mapping to a 9-cM region on chromosome
20, between the markers D20S477 andD20S850, in four
ICF patients. Further delimitation of this region will re-
quire more families and the use of additional polymor-
phic DNAmarkers. However, the scarcity of ICF families
is the major limiting factor.
Two enzymes, encoded by genes in the 20q region,
that are possibly involved in the methylation of DNA
were investigated: ADA and ACHY (or SAHH). ADA
and SAHH deficiency can lead to increased intracellular
concentrations of deoxy-adenosine and S-adenosyl-L-
homocysteine, respectively. These metabolites are
known inhibitors of crucial methyl transfer reactions by
S-adenosyl-L-methionine, involved in DNA methylation
(Ueland 1982). The normal enzyme activities of both
ADA and SAHH in our ICF patients excluded their genes
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as candidates for ICF. Since, in the mouse, the lethal
nonagouti (ax) mutation is a recessive lethal mutation,
we could expect the complete loss of SAHH activity to
be lethal in humans. This mouse mutation is a deletion
of the achy gene, which results in complete loss of SAHH
activity (Miller et al. 1994).
The 20q region defined by our mapping studies is still
too large to make positional cloning feasible. However,
several ESTs of unknown function have been assigned
to the region. However, a search for other genes encod-
ing enzymes involved in DNA methylation is attractive,
as this could provide further insight into fundamental
biological processes. Our results confirm the effective-
ness of homozygosity mapping as a tool for gene local-
ization of rare inbred disorders.
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